Charles Schwab Investment Management Inc. Has $4.77 Million Holdings in uniQure (NASDAQ:QURE)

Charles Schwab Investment Management Inc. decreased its holdings in shares of uniQure (NASDAQ:QURE) by 2.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 269,980 shares of the biotechnology company’s stock after selling 7,295 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.55% of uniQure worth $4,768,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of QURE. China Universal Asset Management Co. Ltd. increased its stake in shares of uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 969 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in uniQure during the fourth quarter valued at approximately $88,000. Geode Capital Management LLC increased its stake in uniQure by 1.3% in the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after purchasing an additional 6,362 shares in the last quarter. RTW Investments LP bought a new stake in uniQure in the third quarter valued at approximately $49,000. Finally, Quarry LP acquired a new stake in uniQure in the third quarter worth $58,000. 78.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on QURE. Mizuho boosted their price target on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 19th. Leerink Partners boosted their target price on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of uniQure in a research report on Tuesday, March 4th. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a research report on Tuesday, January 21st. Finally, Wells Fargo & Company dropped their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $38.89.

uniQure Trading Down 2.8 %

NASDAQ:QURE opened at $14.36 on Wednesday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The company has a market cap of $776.55 million, a P/E ratio of -2.90 and a beta of 0.36. The business has a 50 day moving average price of $13.83 and a two-hundred day moving average price of $10.66.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the completion of the transaction, the chief executive officer now directly owns 651,454 shares of the company’s stock, valued at approximately $6,703,461.66. This represents a 4.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Christian Klemt sold 10,438 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the transaction, the chief financial officer now owns 217,730 shares of the company’s stock, valued at approximately $2,240,441.70. This represents a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 90,830 shares of company stock worth $961,401. 4.74% of the stock is owned by insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.